Lexeo Therapeutics, Inc. (NASDAQ: LXEO) has successfully priced its underwritten public offering and concurrent private placement, resulting in gross proceeds of approximately $135 million. The public offering included 15,625,015 shares of common stock at an offering price of $8.00 per share. Additionally, Lexeo agreed to sell pre-funded warrants to purchase 1,250,000 shares of common stock to Balyasny Asset Management at a price of $7.9999 per pre-funded warrant in a private placement.
The offering and concurrent private placement are expected to close on or about October 20, 2025. Leerink Partners, Cantor, Stifel, and Oppenheimer & Co. are acting as joint book-running managers for the public offering, while Baird is acting as the lead manager.
The public offering is being made pursuant to a registration statement on Form S-3, and Lexeo has filed a preliminary prospectus supplement and accompanying prospectus relating to the offering with the U.S. Securities and Exchange Commission (SEC). The final prospectus supplement and accompanying prospectus will also be filed with the SEC.
Lexeo Therapeutics is a clinical stage genetic medicine company focused on developing treatments for cardiovascular diseases. The company is advancing a portfolio of therapeutic candidates targeting the underlying genetic causes of conditions, including LX2006 in Friedreich ataxia (FA) cardiomyopathy and LX2020 in plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy.
The successful pricing of the public offering and concurrent private placement reflects investors' confidence in Lexeo's portfolio of therapeutic candidates and its dedication to reshaping heart health through genetic medicine. As a result of these announcements, the company's shares have moved -0.68% on the market, and are now trading at a price of $8.77. For the full picture, make sure to review Lexeo Therapeutics's 8-K report.
